SAGE PRO

Home / Research / Sai Life Sciences

SAGE PRO · ORIGINAL EQUITY RESEARCH

Sai Life Sciences — Q2 FY27 Results Analysis

WATCH at ₹1,804.10

Published · Quarter Q2 FY27 · SAILIFE

FY26 P/E108.5x
H1 capex₹621cr
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Q2 growth accelerated

Q2 FY26537.47 value
Q1 FY27554.29 value
Q2 FY27658.59 value

Issuer Q2 results/deck; analyst calculations

CHART 2

H1 sales +17%

H1 FY26₹1,033.89 cr
H1 FY27₹1,212.87 cr

Issuer Q2 results/deck; analyst calculations

CHART 3

CDMO and CRO

CDMO64 value
CRO36 value

Issuer Q2 results/deck; analyst calculations

CHART 4

Commercial conversion

Commercial34 value
Late stage14 value

Issuer Q2 results/deck; analyst calculations

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

WATCH at ₹1,804.10

Strong growth but high expectations and negative cash after capex

Watch: Track commercial conversion and cash

RESEARCH INSIGHT

Q2 growth accelerated

Broad-based CRO and CDMO growth

Watch: Verify H2 growth

RESEARCH INSIGHT

H1 sales +17%

Revenue increase of ₹179 crore

Watch: Compare H2 hurdle

RESEARCH INSIGHT

CDMO and CRO

Rounded management mix, not separate statutory segments

Watch: Track mix and contribution

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Research date: 16 November 2026 | NSE: SAILIFE | Reference price: ₹1,804.10 (Sage PRO, intraday quote, 16 November 2026)

1. Investment decision and variant thesis

Key takeaways

  • Rating: WATCH — strong business momentum, demanding price and a capital-heavy transition. Sai Life Sciences is a small-molecule-led integrated contract research, development and manufacturing organisation.
  • Its strategic advantage is the ability to retain a customer from discovery through process development, clinical supply and commercial manufacture.
  • Q2 FY27 confirms healthy growth in both research and manufacturing: consolidated sales of ₹658.59 crore, up 22.5% YoY; management-defined EBITDA including forex of approximately ₹187 crore, up 20%; PAT ₹98.32 crore, up 17.3%.

However, the same quarter reveals the tension between attractive long-duration demand and the cost of building capacity ahead of utilisation. First-half reported capital expenditure of ₹621 crore is more than three times statutory operating cash flow of ₹190 crore. Borrowings excluding leases increased from ₹95.13 crore in March to ₹448.24 crore in September.

At ₹1,804.10, FY26 basic EPS ₹16.63 implies 108.5x P/E; H1 EPS ₹8.09 annualised implies 111.5x. After November option allotment, approximately 21.258 crore shares imply equity value ₹38,352 crore. Chapter 6 details scenario hurdles.

2. Business model, differentiation and economic moat

Key takeaways

  • Sai operates along the drug-development value chain.
  • CRO work includes medicinal chemistry, biology, DMPK, analytical and integrated discovery activities.
  • Development bridges discovery and the commercial phase through process chemistry, scale-up, route optimisation and clinical manufacturing.

CDMO includes late-stage and commercial production, with a particular small-molecule capability. The strategic value of the platform is knowledge continuity: when an existing discovery customer progresses, the supplier may already understand the molecule, experimental history, impurity controls and cost drivers. This can shorten transfer time and lower the client's execution risk. It is not a legal guarantee that the customer awards the next stage.

The September deck identifies 300+ active customers, including 19 of the top 25 global pharma companies by market cap, 4,400+ employees, and research/manufacturing across Hyderabad, Bidar, Manchester and Boston. Its 34 commercial NCEs, 14 Phase III/pre-registration molecules, five discovery-to-market molecules and 50+ advanced programmes indicate pipeline depth, not disclosed product-level cash flows.

One late-phase molecule moved to commercial in Q2; gross progression does not mean the net commercial count grew. Track conversion, repeat sales and attrition. Peptides, ADCs and oligonucleotides expand technical opportunity but require validated processes and customer orders before earning a commercial valuation.

CRO needs skilled billable teams and laboratory utilisation; CDMO needs qualified reactors, quality systems and commercial volume. The integrated model can deepen customer lifetime value, yet a strategic framework is not a committed order book.

Compared with Anthem's higher-margin commercial mix and Syngene's broader discovery/biologics footprint, Sai's case rests on concurrent CRO/CDMO growth and conversion of its new small-molecule capacity. Compare incremental return, cash conversion and qualified utilisation, not a single sector multiple.

3. Financial performance: consolidated statutory reconciliation

Key takeaways

  • Amounts in INR crore, except EPS.
  • Source: November 5 consolidated financial results, unaudited and limited-reviewed; issuer presentation/earnings release for management EBITDA and material margin.
  • Rounded rows may not sum exactly.
MetricQ2 FY27Q1 FY27Q2 FY26H1 FY27H1 FY26FY26
Operating revenue658.59554.29537.471212.871033.892192.49
Other income3.973.5415.337.5125.2349.13
Materials + inventory change174.69144.91140.12319.60281.23570.89
Employee expense198.06179.90162.79377.96323.41683.06
Other expenses99.4581.4788.73180.92162.49307.39
Operating EBITDA, derived186.38148.00145.84334.39266.76631.15
Depreciation/amortisation48.1345.9439.7594.0777.47166.86
Finance cost10.947.649.3518.5821.7239.24
PBT before exception131.2897.97112.05229.25192.80474.19
PBT after exception131.2897.97112.05229.25192.80466.19
Tax32.9624.6928.2157.6548.50117.28
PAT98.3273.2983.84171.60144.30348.91
Basic EPS, Rs4.633.464.018.096.9116.63

Accounting check: derived operating EBITDA is operating revenue less cost of materials plus inventory movement, employee expense and other expenses; it excludes all other income and adds back neither an arbitrary adjustment nor OCI. The statutory PBT bridge is operating EBITDA + other income − depreciation − finance costs − exceptional items.

For Q2: ₹186.38 + ₹3.97 − ₹48.13 − ₹10.94 = ₹131.28 crore. Management shows EBITDA including forex of ₹187 crore versus ₹156 crore in Q2 FY26 and ₹335 crore versus ₹281 crore in H1. The statutory derived operating EBITDA is therefore not identical to management's metric, especially in prior periods.

Comparisons use a consistent definition. Statutory derived margin is 28.3% Q2 versus 27.1% prior year; the issuer's rounded EBITDA margin is 28% versus 29%. This is not a contradiction when definitions differ.

Revenue, mix and sequential growth

Q2 revenue increased by ₹121.12 crore YoY and ₹104.30 crore sequentially. Growth was 22.5% YoY and 18.8% QoQ. H1 revenue increased 17.3%, while FY26 revenue was ₹2,192.49 crore. Q2 sales growth was broad-based: management reports CDMO +20% and CRO +28%. Based on rounded Q2 mix of 64% CDMO and 36% CRO, approximately ₹421.5 crore and ₹237.1 crore of sales respectively; these are inferred estimates, not independently reported statutory segment figures. H1 mix is 62% CDMO/38% CRO, implying approximately ₹752 crore and ₹461 crore. The company reports one operating segment under Ind AS 108; therefore do not present management business mix as separate audited segment accounts.

Employee expenses increased ₹35.27 crore YoY, about 21.7%, broadly in line with sales. Materials plus inventory change increased ₹34.57 crore, about 24.7%, somewhat above revenue. Other expenses increased ₹10.72 crore, about 12.1%, supporting operating leverage.

Derived EBITDA rose approximately ₹40.54 crore, or 27.8%; incremental margin on additional sales roughly 33.5%. Q2 PBT grew 17.2% and PAT 17.3%, below sales growth, because depreciation increased and other income declined substantially.

Q2 PAT margin was 14.9% versus 15.6% last year. New assets generate depreciation before peak production; management EBITDA can look healthy while per-share cash outcomes lag.

Operating cash and investment bridge

H1 CFO after tax was ₹190.13 crore versus ₹92.84 crore, more than doubling. This is approximately 111% of PAT versus 64% last year. Pre-working-capital operating cash was ₹345.61 crore versus ₹283.28 crore; working-capital and other operating adjustments reduced the amount before tax to ₹214.14 crore. Inventory consumed ₹91.08 crore and other current assets consumed ₹60.79 crore; receivables released ₹19.78 crore versus a prior-year use of ₹136.47 crore. The current cash improvement partly reflects easier collection comparison and should not be extrapolated as a permanent doubling in operating cash.

Statutory cash purchases of PPE, intangible assets and associated capital items were ₹561.29 crore in H1, versus ₹247.61 crore. CFO less those purchases was negative ₹371.16 crore, versus negative ₹154.77 crore.

This is a transparent cash proxy before financing, not audited free cash flow to equity. Management-reported H1 capex of ₹621 crore is not identical to cash purchases: differences may reflect accruals, timing, capital creditors and scope.

Use statutory cash flow for liquidity and management capex for execution; do not subtract both. On management capex basis, CFO minus spend is negative ₹430.87 crore. Both demonstrate an investment-intensive year.

4. Balance sheet, capex milestones and capital-return analysis

Key takeaways

  • Assets rose to ₹4,202.27 crore from ₹3,626.14 crore; equity to ₹2,688.06 crore.
  • PPE plus CWIP rose ₹495.32 crore; CWIP doubled to ₹559.60 crore, not yet qualified productive capacity.

September borrowings: non-current ₹30.31 crore plus current ₹417.94 crore, total ₹448.24 crore; March equivalents ₹20.50 crore and ₹74.62 crore, total ₹95.13 crore. Leases total ₹171.33 crore versus ₹193.33 crore.

Cash and equivalents are ₹30.92 crore, other bank balances ₹28.56 crore and current investments ₹48.48 crore; do not automatically classify all financial assets as freely available cash. A conservative narrow net debt excluding leases is borrowings minus cash, ₹417.32 crore, versus ₹13.21 crore in March.

Including leases and subtracting cash gives ₹588.65 crore. Borrowings/equity approximately 16.7% versus 3.8%. Current assets ₹1,440.53 crore and current liabilities ₹1,184.75 crore imply 1.22x current ratio versus 1.69x in March.

A large part of current assets consists of other current assets and inventory; this is not an equivalent cash coverage ratio. Short-term refinancing and working-capital discipline deserve monitoring.

Inventory rose from ₹150.97 crore to ₹242.05 crore, current receivables fell from ₹373.62 crore to ₹342.22 crore and trade payables (MSME + other) fell from ₹285.34 crore to ₹272.80 crore. The simple inventory plus receivables less payables proxy rose from ₹239.25 crore to ₹311.47 crore.

Cash-flow changes differ from period-end changes due to currency and other reconciliations. Approximate receivables days using annualised H1 sales and September ending receivables are 51.5 days, not contractual DSO.

Monitor unbilled contract assets in other current assets, inventory linked to firm orders, ageing and collections. A growing commercial pipeline may legitimately require inventory, but capital committed before qualification or demand introduces risk.

Capacity timeline

The issuer reports ₹621 crore H1 FY27 capital spend, ₹358 crore in Q2, and a ₹1,100–1,300 crore full-year plan. H2 residual implied spend is ₹479–679 crore; midpoint ₹579 crore. The first-half investment is 51.2% of revenue and 185.4% of management EBITDA. These ratios will not remain economically attractive without a meaningful ramp or subsequent capex moderation.

Bidar's additional 220 KL small-molecule capacity is ready and completing quality trials, with management expecting revenue contribution during FY27. The additional 225 KL phase is now expected early Q3 FY28 rather than the earlier timeline.

Management links the shift to project prioritisation and says it does not expect FY28 revenue commitments to be affected. This is a forecast, not evidence of completed utilisation. A new Telangana site is in design, with groundbreaking expected Q4 FY27.

These three projects have distinct milestones and cash obligations: ready/qualify/produce, deferred capacity commissioning, and design/break ground. Model them separately, and do not capitalise all future plant sales in FY27.

Incremental return hurdle

On ₹1,200 crore illustrative FY27 capex, a 15% post-tax incremental return requires ₹180 crore annual NOPAT after assets mature. At 25% tax this is ₹240 crore EBIT. With an analyst assumption of ₹90–120 crore incremental depreciation, incremental EBITDA needs ₹330–360 crore. At 30% incremental operating margin, approximately ₹1,100–1,200 crore incremental annual sales are required. At 25% margin, ₹1,320–1,440 crore. This is a capital hurdle, not management guidance; some capex replaces existing assets or builds capabilities rather than directly creating a new sales stream. The calculation nevertheless illustrates the importance of project-linked return and timing. If capacity ramps slowly, the company can incur depreciation, fixed operating costs and borrowing interest before realising cash. An investment committee should request a reconciliation of growth capex, maintenance capex, productive commissioning, qualification and realised commercial contribution.

5. Management intelligence and strategic execution

Key takeaways

  • The November call's most useful distinction is that management aims to expand relationships from discrete services into end-to-end engagement.
  • One customer relationship began operations after being announced previously and a second was broadened.
  • Management emphasised large-pharma traction and an increase in biotech enquiries.

The first integrated collaboration is expected to be fully functional during Q3. The correct tracking metric is not number of partnerships alone but billable work, cross-sell across functions, retention and commercial progression. Broad service coverage can increase customer lifetime value, while concentration can rise if a few strategic customers dominate incremental capacity. Ask for aggregate revenue mix and top-customer exposure rather than demanding confidential contract details.

FY26 H2 sales were ₹1,158.60 crore. A 20% FY27 growth illustration requires ₹1,418.12 crore H2 (+22.4% YoY); 25% growth requires ₹1,527.75 crore (+31.9%). Repeating Q2 sales twice yields approximately ₹2,530 crore FY27, +15.4%. These analyst bridges are not guidance.

During the call management discussed raw material and solvent pressure linked to supply disruption, with efforts to recover costs from customers. Pass-through mechanisms differ by contract, and timing matters.

An initial cost increase can compress quarterly contribution even if recoverable later. Monitor material margin, receivable ageing and customer recoveries rather than assuming every increase is immediately offset.

The company stated capacity commissioning has been reprioritised according to customer requirements. A delay can be disciplined if demand timing shifts, but can also weaken revenue ramp if qualification is later than expected.

The decisive evidence will be commercial batch commencement and realised revenue.

6. Valuation, scenarios and portfolio decision

Key takeaways

  • Analyst FY28 scenarios, not guidance or consensus. FY26 revenue base ₹2,192 crore.
  • Assume FY28 sales ₹3,000/3,600/4,200 crore (two-year CAGR approximately 17%/28%/38%), derived operating margins 24%/29%/32%, other income ₹15/20/25 crore, D&A ₹300/330/360 crore, finance expense ₹55/45/40 crore, tax 25% and 21.5 crore shares.
  • These assumptions reflect different absorption of the capacity build and future financing; they are deliberately not a claim about contracted orders.
FY28 assumptionBearBaseBull
Revenue, ₹cr300036004200
Operating EBITDA margin24%29%32%
Operating EBITDA, ₹cr72010441344
Other income152025
D&A300330360
Finance cost554540
PBT380689969
PAT after 25% tax285516.75726.75
EPS on 21.5 crore shares13.2624.0333.80
Illustrative P/E35x50x65x
Implied value, ₹46412022197
Versus ₹1804.10-74%-33%+22%

The bear case models capacity and funding costs outrunning revenue: PAT below FY26 despite larger revenue. The base case assumes robust 28% compound sales growth and good operating absorption, but even that earnings trajectory requires a very high multiple for the reference price to offer a favourable return.

The bull case assumes successful customer conversion, strong commercial supply and 32% operating margin; it also relies on the market preserving 65x FY28 earnings. Scenario multiples are analytical assumptions, not historical norms or observed peer values.

The estimates exclude dividends and discounting and are not probability-weighted targets.

Reverse underwriting at 50x: price ₹1,804.10 requires EPS ₹36.08, PAT ₹775.76 crore on 21.5 crore shares. At 25% tax PBT must be ₹1,034.35 crore. Add base D&A and finance, subtract other income: required operating EBITDA ₹1,389.35 crore.

At 29% margin, sales required ₹4,791 crore, implying FY26-FY28 CAGR about 48%. At 65x, reference price requires EPS ₹27.76, or PAT about ₹597 crore; with base cost assumptions, required sales about ₹3,971 crore.

The hurdle depends heavily on terminal multiple. A high valuation may persist if commercial growth becomes durable and cash returns prove strong, but that is precisely the evidence investors must demand.

7. Risks, catalysts, monitoring and source ledger

Key takeaways

  • Risk register. (1) Capacity execution: Bidar quality trials and commercial batch timing; 225 KL phase moved to FY28.
  • Watch project-specific qualification and realised sales rather than nominal KL.
  • (2) Funding: rising current borrowing and lower cash, potential refinancing or additional interest; monitor debt, CFO, capex and covenant/credit disclosures.

(3) Scientific risk: clinical failure, product launch timing and commercial allocation can interrupt expected conversion. (4) Customer concentration: strategic contracts may increase exposure to a small group; track aggregate concentration, diversification and repeat demand. (5) Cost/quality: solvent inflation, pass-through delays, inspections, contamination or data integrity; monitor official regulatory and quality disclosures. (6) Margin/valuation: cost absorption may improve, but multiple compression can erase operating gains. (7) Dilution: stock option allotments change EPS denominator. (8) Currency: separate operating margin from forex and hedge/OCI items. (9) Reinvestment: negative cash after capital purchases may persist during growth capex; require a path to owner cash after commissioning.

Original evidence and review status

S1. Sai Life Sciences, 5 November 2026 board-approved Q2/H1 FY27 financial results, consolidated statement, balance sheet, cash flow, notes and limited review: Statutory text and the consolidated P&L page visually checked; financial calculations use the consolidated tables. S2. Investor presentation dated 5 November 2026, filed 6 November: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=15530947-ecd4-4f8d-99b5-3d59b47f1e78.pdf. Sage PRO canonical 75651, current semantic ACCEPT and full-token scored. Operational mix, 67% utilisation, pipeline, capex, customer and capacity evidence. S3. Earnings call held 6 November, available 12 November: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=89557f77-2b3c-497b-99e7-f2bb3b3a05cf.pdf. Canonical 90392, current semantic ACCEPT and full-token scored. Integrated service versus programme, 220/225 KL timing, material costs and H2 outlook. S4. Issuer earnings release, 5 November 2026: Reconciles management rounded revenue, EBITDA and PAT. S5. Q1 FY27 investor presentation, available 11 August: https://www.bseindia.com/xml-data/corpfiling/AttachHis/9b86f38d-7a42-4a09-8c5d-4bf013f94a85.pdf (9746). Q1 call: https://www.bseindia.com/xml-data/corpfiling/AttachHis/597af4ad-26ff-4921-8230-e5c8bcc718f3.pdf (9747). Statutory Q1 comparative columns are the financial baseline. S6. Sage PRO price observation 16 November 2026, ₹1,804.10. Intraday quote, not certified closing price; refresh before investing.

This source-verified longform is not independently QA-approved. Full source-page parity, independently verified peer multiples and owner-cash DCF remain open.

Additional company evidence

CHART 5

Derived operating EBITDA

Q2 FY26145.84 value
Q1 FY27148 value
Q2 FY27186.38 value

Issuer Q2 results/deck; analyst calculations

CHART 6

PAT grew slower than sales

Q2 FY26₹83.84 cr
Q1 FY27₹73.29 cr
Q2 FY27₹98.32 cr

Issuer Q2 results/deck; analyst calculations

CHART 7

Material costs and mix

Q2 FY26397 value
Q2 FY27484 value

Issuer Q2 results/deck; analyst calculations

CHART 8

CFO improved

H1 FY2692.84 value
H1 FY27190.13 value

Issuer Q2 results/deck; analyst calculations

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Q2 investor presentation
  2. Q2 earnings call

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.